|
Market Closed -
Other stock markets
|
Pre-market 02:15:52 am | |||
| 263.50 EUR | +1.93% |
|
265.00 | +0.57% |
| Jun. 25 | US prices for new drugs fell in 2025 as fewer costly gene therapies were launched | RE |
| Jun. 22 | UBS Trims UCB's PT, Affirms Buy Rating | MT |
Published on 05/04/2026 at 05:11 pm EDT
Health-care companies fell amid anxiety about earnings.
Pfizer shares slipped ahead of the drug giant's earnings report.
Belgian biopharmaceutical firm UCB agreed to buy Candid Therapeutics for up to $2.2 billion, part of UCB's efforts to expand a portfolio of treatments for autoimmune and inflammatory diseases.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
05-04-26 1710ET
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
